Crossmark

: A.G. has occasionally consulted for Amolyt, Abiogen, Alexion, Crinetics, Ipsen, Pfizer and Recordati Rare Diseases, and received research grants to the Istitution by Recordati Rare Diseases. L.d.F. received a research grant to their institution from Abiogen Pharma S.p.A. and his research activities are partly supported by Glucocorticoid induced Osteoporosis Skeletal (GIOSEG). M.F. received grants to their institution from Amryt, Crinetics, Ionis and Recordati Rare Diseases, received occasional consulting fees or has served as occasional Advisory Board Member for Amryt, Crinetics, Camurus, Ipsen, and Recordati Rare Diseases. S.P. has been a speaker at workshops and/or advisory board member for HRA Pharma, Ipsen, Lilly, Novo Nordisk, Pfizer, and Recordati Rare Diseases. S.L.S. is principal investigator for Chiasma (Chiesi) and Pasireotide (Novartis, now Recordati Rare Diseases). C.L.B. has received speaking fees from Ipsen, consulting fees from Ipsen, Recordati Rare Diseases and Novo Nordisk, and is a principal investigator of clinical trials of Crinetics. A.J.v.d.L. has received consulting and speaking fees from Amolyt Pharma, Pfizer. M.G. has received speakers honoraria from Ipsen and Pfizer. K.S. has received honoraria for consulting, speaking and scientific projects from the following companies: Pfizer, Recordati Rare Diseases, Camurus, Crinetics, Novo Nordisk, Ascendis. D.F. received fees for lecture and advisory boards from Novartis, Camurus, Recordati Rare Diseases. M.R.G. has received speaker fees from Recordati Rare Diseases, Ipsen and Novo Nordisk, is member of the advisory board of Recordati Rare Diseases, Ipsen, Novo Nordisk and Crinetics, is principal investigator in clinical trials from Recordati Rare Diseases and Crinetics. A.G.I. occasionally consults for Crinetics, Camurus and Xeris, has received research grants to their institution from Recordati Rare Diseases, Xeris, Chiesi. C.J.S. is an advisory board member or recipient of speaker’s fees from NovoNordisk, Amolyt, Pfizer, Crinetics, Sandoz-Hexal, Recordati Rare Diseases, Debiopharm and ConsilientHealth. P.K. participated in clinical trials of Carmus and Recordati Rare Diseases. . P.M. has been a principal investigator in clinical trials of Ipsen, Pfizer, Camurus, received consultation fee and research support from Pfizer, Recordati Rare Diseases. N.K. has been a speaker for Pfizer, Ipsen, Recordati Rare Diseases, investigator for Pfizer, Ipsen, scientific advisory board for Pfizer, Ipsen, Recordati Rare Diseases. S.C. has received lecture and advisory fees and grants from Ipsen, Recordati Rare Diseases. A.L. has received lecture fees from Ipsen and served as consultant for NovoNordisk. Y.G. participated in clinical trials of Crinetics, Cortendo, Debiopharm and Ascendis. E.V. is on the advisory board for Recordati Rare Diseases, HRA pharma, received speaker fees from Recordati Rare Diseases, HRA Pharma, Ipsen. S.F. has received consultancy and speaker fees from Ipsen and Pfizer, consultancy fee from Novartis, is an advisory board member for Recordati Rare Diseases and Novo Nordisk, and has received grants to their institution from Abiogen Pharma S.p.A. P.C. has received unrestricted research and educational grants from Ipsen, Recordati Rare Diseases, Advanz and Pfizer, is an investigator (principal or coordinator) for clinical trials funded by Chiasma, Recordati Rare Diseases, Pfizer, Crinetics and Debiopharm, is a member of Advisory Boards from Pfizer, Crinetics, Recordati Rare Diseases and Amolyt, lectures for Ipsen, Recordati Rare Diseases and Pfizer. T.B. is clinical trial investigator for Xeris, Crinetics, Debiopharm, Recordati Rare Diseases, is on advisory boards for Pfizer, Recordati Rare Diseases, Novo-Nordisk, received speaker fees from Pfizer, Recordati Rare Diseases, Novo-Nordisk and received research grants from Pfizer. A.C. is a principal investigator of research studies for Novartis, Ipsen, Pfizer, a consultant for Novartis, Ipsen, Pfizer, received honoraria from Novartis, Ipsen and Pfizer. S.N. has received consulting, research and speaking fees from Novo Nordisk, Crinetics, Recordati Rare Diseases, Pfizer. M.P.-D. received funding for advisory board or lectures given at symposia organized by Recordati Rare Diseases, Pfizer, Novartis and Ipsen. S.M. received a research grant to their institution from Recordati Rare Diseases; is a consultant to Ionis, Camurus, NovoNordisk, Chiesi. A.G. is Editor in Chief of Pituitary. L.D.F, R.P. and A.G.I., are Associate Editors of Pituitary. The other authors declare no competing interests.

Document is current

Any future updates will be listed below